EirGen Pharma Revenue and Competitors

EirGen Pharma focuses on the development, registration and commercial manufacture of high potency, high barrier to entry solid dose products for the global pharmaceutical market. EirGen Pharma is fully licensed to manufacture oncology, cytotoxic, steroidal and immunosuppressant molecules in a purpose built high containment facility. The state of the art facilities can also handle the development of moisture sensitive molecules in a low humidity environment. The company has an Investigational Medicinal Products (IMP) licence for the manufacture of clinical trial materials and a Manufacturing Licence for commercial manufacturing and packaging. These licences specifically relate to highly potent products. In May 2015 EirGen Pharma was acquired by OPKO Health, Inc., who is headquartered in Miami. OPKO is a publically traded healthcare company involved in the discovery, development, and commercialization of next-generation diagnostics, pharmaceuticals, and vaccines. OPKO focuses on unmet medical need related to neurological disorders, infectious diseases, and oncology. OPKO actively explores opportunities to acquire complementary pharmaceutical compounds and technologies, which could, individually or in the aggregate, materially increase the scale of its business. OPKO also explores strategic opportunities in other medical markets that would allow it to take advantage of its business and global distribution expertise. High Potency Pharmaceutical Products, Oncology & Cytotoxic products, EMA, FDA & PMDA approved facility, HIgh Containment product development & manufacture